Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes

Open access

Abstract

OBJECTIVE: To examine the associations between patient out-of-pocket (OOP) costs and nonadherence to glucagon-like peptide 1 receptor agonists (GLP-1RA), and the consequent impact on adverse outcomes, including hospitalizations and emergency department (ED) visits. RESEARCH DESIGN AND METHODS: This retrospective cohort study used MarketScan Commercial data (2016–2021). The cohort included nonpregnant adults aged 18–64 years with type 2 diabetes who initiated GLP-1RA therapy. Participants were continuously enrolled in the same private insurance plan for 6 months before the prescription date and 1 year thereafter. Exposures included average first 30-day OOP costs for GLP-1RA, categorized into quartiles (lowest [Q1] to highest [Q4]). Primary outcomes were the annual proportion of days covered (PDC) for GLP-1RA and nonadherence, defined as PDC <0.8. Secondary outcomes included diabetes-related and all-cause hospitalizations and ED visits 1 year after GLP-1RA initiation. RESULTS: Among 61,907 adults who initiated GLP-1RA, higher 30-day OOP costs were associated with decreased adherence. Patients in the highest OOP cost quartile (Q4: $80–$3,375) had significantly higher odds of nonadherence (odds ratio [OR] 1.25; 95% CI 1.19–1.31) compared with those in Q1 ($0–$21). Nonadherence was linked to increased incidence rates of diabetes-related hospitalizations or ED visits (incidence rate ratio [IRR] 1.86; 95% CI 1.43–2.42), cumulative length of hospitalization (IRR 1.56; 95% CI 1.41–1.72), all-cause ED visits (IRR 1.38; 95% CI 1.32–1.45), and increased ED-related costs ($69.81, 95% CI $53.54–$86.08). CONCLUSIONS: Higher OOP costs for GLP-1RA were associated with reduced adherence and increased rates of adverse outcomes among patients with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc24-2746

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. U.S. Food and Drug Administration, 2023, Medications containing semaglutide marketed for type 2 diabetes or weight loss. January, 202
  2. Schulte, 2023, Association of insurance characteristics and persistence with anti-obesity and GLP-1 RA medications, Obesity, 31, 36

Cited by

See all 14

Metadata

Authors
Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., Grams, M. E., Wright, D. R., Wang, V. H.-C., Rajan, A., Butt, E., Shin, J.-I., Xu, Y., Chhabra, K. R., & Divers, J.
Affiliations
  • NYU Grossman Long Island School of Medicine (US)
  • New York University (US)
  • Harvard University (US)
  • Johns Hopkins University (US)
  • Bellevue Hospital Center (US)
Corresponding author
Zhang, Donglan
Venue
Diabetes Care
Published
2025-04-09
Volume
48
Issue
8
Pages
1329-1336
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W4409283716
Cited by
14
References
35
Citations by year
2026: 10 · 2025: 4
FWCI
18.67
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Doucette Innovation Fund
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
Keywords
patient cost sharing, out-of-pocket costs, GLP-1 receptor agonists, medication adherence, type 2 diabetes, hospitalization, emergency department visits, health care costs, insurance coverage, proportion of days covered
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Diabetes Mellitus, Type 2, Emergency Service, Hospital, Female, Hospitalization, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Cost Sharing, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes. https://app.cochat.ai/papers/10.2337/dc24-2746
The paper
Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., Grams, M. E., Wright, D. R., Wang, V. H.-C., Rajan, A., Butt, E., Shin, J.-I., Xu, Y., Chhabra, K. R., & Divers, J. (2025). Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes. Diabetes Care. https://doi.org/10.2337/dc24-2746

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.